© The Canadian Journal of Urology™; 21(Supplement 2); June 2014
44. Oekle M, Bachmann A, Descazeaud A et al. EAU guidelines
on the treatment and follow-up of non-neurogenic male lower
urinary tract symptoms including benign prostatic obstruction.
Eur Urol
2013;64(1):118-140.
45. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release
attenuates lower urinary tract symptoms in men with benign
prostatic hyperplasia.
J Urol
2005;174(6):2273-2275.
46. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine
and tamsulosin for treatment of men with lower urinary
tract symptoms and overactive bladder.
JAMA
2006;296(19):
2319-2328.
47. Yokoyama T, Uematsu K, Watanabe T et al. Naftopidil and
propiverine hydrochloride for treatment of male lower urinary
tract symptoms suggestive of benign prostatic hyperplasia and
concomitant overactive bladder: a prospective randomized
controlled study.
Scand J Urol Nephrol
2009;43(4):307-314.
48. Gittens PR, Lallas CD, Pe ML et al. Uropharmacology for the
primary care physician.
Can J Urol
2008;15(Suppl 1):78-91.
49. Rittmaster RS, Norman RW, Thomas LN et al. Evidence for
atrophy and apoptosis in the prostates of men given finasteride.
J Clin Endocrinol Metab
1996;81(2):814-819.
50. Naslund MJ, Miner M. A review of the clinical efficacy and
safety of 5a-reductase inhibitors for the enlarged prostate.
Clin Ther
2007;29(1):17-25.
51. Nickel JC, Gilling P, Tammela T et al. Comparison of dutasteride
and finasteride for treating benign prostatic hyperplasia: the
Enlarged Prostate International Comparator Study (EPICS).
BJU Int
2011;108(3):388-394.
52. Roehborn C, Siami P, Barkin J et al. The effects of combination
therapy with dutasteride and tamsulosin on clinical outcomes
in men with symptomatic benign prostatic hyperplasia: 4-year
results from the combat study.
Eur Urol
2010;57(1):123-131.
53. Kaplan SA, Roehrborn CG, McConnel JD et al. Long-term
treatment with finasteride results in a clinically significant
reduction in total prostate volume compared to placebo over
the full range of baseline prostate sizes in men enrolled in the
MTOPS trial.
J Urol
2008;180(3):1030-1032.
54. Roehrborn CG, Casasbe A, Da Pozza L et al. Combination
therapy with finasteride and tadalafil once daily for 6 months: A
randomized, placebo-controlled study inmenwith lower urinary
tract symptoms secondary to benign prostatic hyperplasia.
Eur Urol Suppl
2013;12:e1096.
55. Morlock R, Goodwin B, Gomez Rey G et al. Clinical progression,
acute urinary retention, prostate-related surgeries, and cost in
patients with benign prostatic hyperplasia talking early versus
delayedcombination5
α
-reductase inhibitor therapyand
α
-blocker
therapy: a retrospective analysis.
Clin Ther
2013;35(5):624-633.
56. AndrioleG, BruchovskyN, ChungLWet al. Dihydrotestosterone
and the prostate: the scientific rational for 5-alpha reductase
inhibitors in the treatment of benign prostatic hyperplasia.
J Urol
2004;172(4 Pt 1):1399-1403.
57. Thompson IM, Goodman PJ, Tangen CM et al. The influence of
finasteride on the development of prostate cancer.
N Engl J Med
2003;349(3):215-224.
24
Rosenberg ET AL.
